



Natural discomfort management

What is Levagen®+?

Levagen®+ is a bioavailable, next-generation form of PEA (Palmitoylethanolamide) designed for superior absorption and formulation flexibility. It utilizes award-winning LipiSpurse® technology, which disperses lipophilic actives in aqueous environments to prevent clumping and improve uptake.

PEA supports the body's natural inflammatory response through activation of PPAR- α and modulation of the endocannabinoid system. Levagen®+ is clinically studied and shown to deliver analgesic and anti-inflammatory benefits, supporting joint comfort, recovery, and overall physical well-being.

Why Levagen®+?

- 300 - 600mg
- Self-affirmed GRAS
- Allergen free (Major 9)
- Vegan / Vegetarian
- Non-GMO
- Halal & Kosher
- Gluten free
- Informed Ingredient

Levagen®+ Benefits

Levagen®+:

- Helps to facilitate recovery from vigorous exercise*
- Supports joint comfort and joint health*
- Helps those with occasional difficulty falling asleep to fall asleep faster*
- Helps to promote feeling awake faster after a night's sleep*
- Supports immune health and respiratory health*
- Supports healthy levels of brain-derived neurotrophic factor (BDNF)*
- Supports cognitive health*
- Supports lower body muscle power*



+1 949 502 5760



sales@saanroo.com



2600 McHale Court, Suite 180
Austin, TX 78758



saanroo.com



*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Published Clinical Studies

2015 Levagen Palmitoylethanolamide launched by Saanroo®
 2017 Levagen+ launched with Pharmako Biotechnologies'
 LipiSpense® platform



PHARMACOKINETIC STUDY

Dosage: 300mg Levagen®+ single dose

Results

- Supports significant increase in plasma PEA concentration
- Levagen®+ showed 1.75x more absorption compared to placebo

EXERCISE RECOVERY STUDY

Dosage: 167.5mg Levagen®+ single dose

Results

- Supports muscle damage and recovery time
- Supports growth through muscle tissue stimulation
- Enhances muscle adaptation
- Reduced blood lactate

PROINFLAMMATORY REDUCTION MARKERS STUDY

Dosage: 600mg Levagen®+ twice daily or a matching placebo for 4 weeks

Results

- Significant reduction in sP-selectin concentrations
- Reduction in IL-1β and IL-2

HEAD DISCOMFORT STUDY

Dosage: 525mg Levagen®+ or a comparable alternative

Results

- Supports significant impact in resolving head discomfort
- Offers significant relief in reducing head discomfort

PERIPHERAL NEUROPATHIC DISCOMFORT STUDY

Dosage: 600mg Levagen®+ daily or a matching placebo for 8 weeks

Results

- Reduction in neuropathic discomfort
- Reduced inflammatory cytokine
- Improved mood and sleep

HEAD DISCOMFORT FOLLOWUP STUDY

Dosage: 600mg Levagen®+ or a matching placebo for a single dose

Results

- Significantly reduced discomfort and resolved head discomfort when compared to placebo

COGNITIVE FUNCTION STUDY

Dosage: 700mg Levagen®+ or a matching placebo for 6 weeks

Results

- Significant improvement in serum BDNF levels when compared to placebo
- Improved memory through better first success and fewer errors

SKIN HEALTH STUDY

Dosage: treatment applied twice daily for 4 weeks

Results

- Significantly reduced redness, dryness and a total POEM score compared to a comparator cream

SPORTS PERFORMANCE STUDY

Dosage: 350mg Levagen®+ or a matching placebo for a single dose

Results

- Development on lean muscle mass
- Significant increase in countermovement jump (CMJ) height

MICROBIOME STUDY

Dosage: 700mg Levagen®+ or a matching placebo for a single dose

Results

- Supports improvement in internal health

2019

2020

2021

2022

2023

2024

2025



JOINT STUDY

Dosage: 300mg or 600mg Levagen® daily or a matching placebo for 8 weeks

Results

- Supports improvement in overall joint health and function
- Supports relaxation and the reduction of daily stress



JOINT DISCOMFORT STUDY

Dosage: 350mg Levagen®+ daily or a matching placebo for 2 weeks

Results

- Significant improvement in joint health in as little as 3 days
- Improvement in QOL

SLEEP STUDY

Dosage: 350mg or a matching placebo for 8 weeks

Results

- Reduced time taken to fall asleep
- Faster time to feel awake
- Improved cognition upon awakening
- Absence of drowsiness

Published Papers:

Health Management,
Alternative to Cannabinoidal

SEASONAL ALLERGY STUDY

Dosage: 350mg or a matching placebo for 2 weeks

Results

- Significant decrease in Plasma histamine, IL-10, IL-8, and TNF-α when compared to baseline
- Supports a significant healthy immune response

IMMUNE STUDY (URTI)

Dosage: 350mg Levagen®+ twice daily or a matching placebo for 2 weeks

Results

- Significantly lower reports of discomfort in relation to number of subjects
- Significantly lower severity of symptoms

MENSTRUAL DISCOMFORT STUDY

Dosage: 350mg or a matching placebo for 16 weeks

Results

- Significant reduction of reported menstrual discomfort at 2-hours post initial dose
- Further significance was seen at 2.5 hours after a second dose

STRESS IN FEMALES STUDY

Dosage: 600mg Levagen®+ twice daily or a matching placebo for 2 weeks

Results

- Significant increase in Standard Deviation of Normal-to-Normal (SDNN) in subjects when compared to placebo
- Supports enhanced physiological stress regulation

TOPICAL JOINT STUDY

Dosage: 1.8mg or a matching placebo for 4 weeks or 5 knee discomfort treatments

Results

- Significantly more events resolved at 60 and 75 minutes
- Significantly lower discomfort score at 60 minutes
- Discomfort reduction at 60 minutes equated to a 55% discomfort reduction relative to baseline

Levagen® and Levagen®+ are registered trademarks of Saanroo®.
LipiSpense® is a registered trademark of Pharmako Biotechnologies.



* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This material is educational in nature and is not intended to serve as regulatory and/or legal advice.



Levagen[®] Formats

Capsules

Tablets

Softgels

Powders

Drinks

Shots

Liquids

Gels

Gummies

Sachets

Ready-to-mix

Effervescent



*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.



Published Clinical Studies

2019



Joint Study

2020



Pharmacokinetic Study



Exercise Recovery Study

2021



Joint Discomfort Study



Sleep Study

2022



Proinflammatory Reduction Markers Study



Head Discomfort Study



Peripheral Neuropathic Discomfort Study

2023



Immune Study



Seasonal Symptom Study

2024



Head Discomfort Followup Study



Cognitive Function Study



Skin Health Study



Sports Performance Study



Microbiome Study

2025



Menstrual Discomfort Study



Stress in Females Study



Topical Spray Study